High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.
McBain, Catherine A
AffiliationBrain Tumour Research Group, Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology & Regenerative Medicine, University of Manchester, Manchester, United Kingdom
MetadataShow full item record
AbstractGlioblastoma (GBM) is the most common primary brain malignancy in adults, yet survival outcomes remain poor. First line treatment is well established, however disease invariably recurs and improving prognosis is challenging. With the aim of personalizing therapy at recurrence, we have established a high content screening (HCS) platform to analyze the sensitivity profile of seven patient-derived cancer stem cell lines to 83 FDA-approved chemotherapy drugs, with and without irradiation.
CitationHigh content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma. 2018, 13(3): e0193694 PLoS One
- A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.
- Authors: Gomez-Roman N, Stevenson K, Gilmour L, Hamilton G, Chalmers AJ
- Issue date: 2017 Feb 1
- High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.
- Authors: Hothi P, Martins TJ, Chen L, Deleyrolle L, Yoon JG, Reynolds B, Foltz G
- Issue date: 2012 Oct
- Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
- Authors: Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L
- Issue date: 2014 May 8
- A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.
- Authors: Visnyei K, Onodera H, Damoiseaux R, Saigusa K, Petrosyan S, De Vries D, Ferrari D, Saxe J, Panosyan EH, Masterman-Smith M, Mottahedeh J, Bradley KA, Huang J, Sabatti C, Nakano I, Kornblum HI
- Issue date: 2011 Oct
- Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.
- Authors: Riedel M, Struve N, Müller-Goebel J, Köcher S, Petersen C, Dikomey E, Rothkamm K, Kriegs M
- Issue date: 2016 Sep 20